FDA Determines Regulatory Review Period for ENSPRYNG Patent Extension

Summary

The US Food and Drug Administration has officially confirmed the regulatory review period for ENSPRYNG, a human biological product, in accordance with the law, following a submission to the US Patent and Trademark Office.